BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.

Canada’s Aeterna Zentaris Inc. said the U.S. FDA approved its oral test to diagnose adult growth hormone deficiency.

Amgen’s PSCK9 inhibitor Repatha continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks. New data shows Repatha hit its primary endpoints and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.

Israeli medical device company Magenta Medical said it has raised $15 million in funding led by Massachusetts-based Abiomed Inc., a maker of catheter-based heart pumps, and venture capital firm Pitango.

Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.

People who typically work much more than 35 to 40 hours a week may be at heightened risk of developing atrial fibrillation, an irregular rapid heartbeat that can lead to strokes, heart failure and chronic fatigue, a recent study suggests.

San Diego-based Arena Pharmaceuticals’ shares rocketed after positive data was announced from its Phase II clinical trial of a drug for pulmonary arterial hypertension (PAH).

Management of heart failure can be overwhelming for patients and their caregivers. To help address this, a new study has been launched assessing patient-facing mobile health technologies to improve adherence to medication and to self-care routines such as physical activity and following fluid and sodium restrictions. Known as the Care Optimization through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT HF), this quality improvement study is enrolling high-risk, hospitalized patients with acute heart failure and reduced ejection fraction.

Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.

Novartis’ heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.